Knockdown of lectin-like oxidized low-density lipoprotein-1 ameliorates alcoholic cardiomyopathy via inactivating the p38 mitogen-activated protein kinase pathway

References

• Mirijello A, Tarli C, Vassallo GA, et al. Alcoholic cardiomyopathy: what is known and what is not known. Eur J Intern Med. 2017;43:1–5. eng.
   PubMed Web of Science ®Google Scholar
• Fernández-Solà J. The effects of ethanol on the heart: alcoholic cardiomyopathy. Nutrients. 2020;12(2): 1-18. eng
   Web of Science ®Google Scholar
• Piano MR. Alcoholic cardiomyopathy: incidence, clinical characteristics, and pathophysiology. Chest. 2002;121(5):1638–1650. eng.
   PubMed Web of Science ®Google Scholar
• Liu B, Zhang R, Wei S, et al. ALDH2 protects against alcoholic cardiomyopathy through a mechanism involving the p38 MAPK/CREB pathway and local renin-angiotensin system inhibition in cardiomyocytes. Int J Cardiol. 2018;257:150–159. eng.
   PubMed Web of Science ®Google Scholar
• Ku BM, Lee YK, Jeong JY, et al. Ethanol-induced oxidative stress is mediated by p38 MAPK pathway in mouse hippocampal cells. Neurosci Lett. 2007;419(1):64–67. eng.
   PubMed Web of Science ®Google Scholar
• Sawamura T, Kume N, Aoyama T, et al. An endothelial receptor for oxidized low-density lipoprotein. Nature. 1997;386(6620):73–77. eng.
   PubMed Web of Science ®Google Scholar
• Reiss AB, Anwar K, Wirkowski P. Lectin-like oxidized low density lipoprotein receptor 1 (LOX-1) in atherogenesis: a brief review. Curr Med Chem. 2009;16(21):2641–2652. eng.
   PubMed Web of Science ®Google Scholar
• Chen M, Kakutani M, Minami M, et al. Increased expression of lectin-like oxidized low density lipoprotein receptor-1 in initial atherosclerotic lesions of Watanabe heritable hyperlipidemic rabbits. Arterioscler Thromb Vasc Biol. 2000;20(4):1107–1115. eng.
   PubMed Web of Science ®Google Scholar
• Pang T, Wang J, Benicky J, et al. Minocycline ameliorates LPS-induced inflammation in human monocytes by novel mechanisms including LOX-1, Nur77 and LITAF inhibition. Biochim Biophys Acta. 2012;1820(4):503–510. eng.
   PubMed Web of Science ®Google Scholar
• Wu Z, Sawamura T, Kurdowska AK, et al. LOX-1 deletion improves neutrophil responses, enhances bacterial clearance, and reduces lung injury in a murine polymicrobial sepsis model. Infect Immun. 2011;79(7):2865–2870. eng.
   PubMed Web of Science ®Google Scholar
• Xu S, Ogura S, Chen J, et al. LOX-1 in atherosclerosis: biological functions and pharmacological modifiers. Cell Mol Life Sci. 2013;70(16):2859–2872. eng.
   PubMed Web of Science ®Google Scholar
• Hu C, Dandapat A, Chen J, et al. LOX-1 deletion alters signals of myocardial remodeling immediately after ischemia-reperfusion. Cardiovasc Res. 2007;76(2):292–302. eng.
   PubMed Web of Science ®Google Scholar
• Mehta JL, Chen J, Hermonat PL, et al. Lectin-like, oxidized low-density lipoprotein receptor-1 (LOX-1): a critical player in the development of atherosclerosis and related disorders. Cardiovasc Res. 2006;69(1):36–45. eng.
   PubMed Web of Science ®Google Scholar
• Lü J, Mehta JL. LOX-1: a critical player in the genesis and progression of myocardial ischemia. Cardiovasc Drugs Ther. 2011;25(5):431–440. eng.
   PubMed Web of Science ®Google Scholar
• Ding Z, Liu S, Wang X, et al. LOX-1, oxidant stress, mtDNA damage, autophagy, and immune response in atherosclerosis. Can J Physiol Pharmacol. 2014;92(7):524–530. eng.
   PubMed Web of Science ®Google Scholar
• Yang D, Liu W, Ma L, et al. Profilin‑1 contributes to cardiac injury induced by advanced glycation end‑products in rats. Mol Med Rep. 2017;16(5):6634–6641. eng.
   PubMed Web of Science ®Google Scholar
• Kryzhanovskii SA, Kolik LG, Tsorin IB, et al. Alcoholic cardiomyopathy: translation model. Bull Exp Biol Med. 2017;163(5):627–631. eng.
   PubMed Web of Science ®Google Scholar
• Luo S, Li G, Geng Z, et al. [Effects of uncoupling protein 2 overexpression on myocardial mitochondrial dynamics in sepsis rats]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2019;31(10):1275–1280. chi.
   PubMedGoogle Scholar
• Zhu W, Zhu F, Zhang B, et al. [Effect of LY249002 on myocardial structure and cardiac function in rats with dilated cardiomyopathy]. Zhong Nan da Xue Xue Bao Yi Xue Ban. 2018;43(1):35–40. chi.
   PubMedGoogle Scholar
• Cederbaum AI. Alcohol metabolism. Clinics in liver disease. 2012;16(4):667–685. eng.
   Google Scholar
• Lê AD, Kalant H. Intravenous self-administration of alcohol in rats-problems with translation to humans. Addict Biol. 2017;22(6):1665–1681. eng.
   PubMed Web of Science ®Google Scholar
• Zhan CY, Tang JH, Zhou DX, et al. Effects of tanshinone IIA on the transforming growth factor β1/Smad signaling pathway in rat cardiac fibroblasts. Indian J Pharmacol. 2014;46(6):633–638. eng.
   PubMed Web of Science ®Google Scholar
• Gonçalves A, Claggett B, Jhund PS, et al. Alcohol consumption and risk of heart failure: the atherosclerosis risk in communities study. Eur Heart J. 2015;36(15):939–945. eng.
   PubMed Web of Science ®Google Scholar
• Wang W, Liu T, Liu Y, et al. Astaxanthin attenuates alcoholic cardiomyopathy via inhibition of endoplasmic reticulum stress-mediated cardiac apoptosis. Toxicol Appl Pharmacol. 2021;412:115378. eng.
   PubMed Web of Science ®Google Scholar
• Tian K, Ogura S, Little PJ, et al. Targeting LOX-1 in atherosclerosis and vasculopathy: current knowledge and future perspectives. Annals of the New York Academy of Sciences. 2019;1443(1):34–53.
   Google Scholar
• Lu J, Wang X, Wang W, et al. LOX-1 abrogation reduces cardiac hypertrophy and collagen accumulation following chronic ischemia in the mouse. Gene Ther. 2012;19(5):522–531. eng.
   PubMed Web of Science ®Google Scholar
• Li X, Tang X, Liu B, et al. LOX-1 deletion attenuates myocardial fibrosis in the aged mice, particularly those with hypertension. Front Cardiovasc Med. 2021;8:736215. eng.
   PubMed Web of Science ®Google Scholar
• Yokoyama C, Aoyama T, Ido T, et al. Deletion of LOX-1 protects against heart failure induced by doxorubicin. PloS one. 2016;11(5):e0154994. eng.
   PubMed Web of Science ®Google Scholar
• Zhang L, Jia YH, Zhao XS, et al. Trichosanatine alleviates oxidized low-density lipoprotein induced endothelial cells injury via inhibiting the LOX-1/p38 MAPK pathway. Am J Transl Res. 2016;8(12):5455–5464. eng.
   PubMed Web of Science ®Google Scholar
• Turner NA, Blythe NM. Cardiac fibroblast p38 MAPK: a critical regulator of myocardial remodeling. J Cardiovasc Dev Dis. 2019;6(3): 1-18. eng
   PubMed Web of Science ®Google Scholar
• Li SY, Li Q, Shen JJ, et al. Attenuation of acetaldehyde-induced cell injury by overexpression of aldehyde dehydrogenase-2 (ALDH2) transgene in human cardiac myocytes: role of MAP kinase signaling. J Mol Cell Cardiol. 2006;40(2):283–294. eng.
   PubMed Web of Science ®Google Scholar
• Kojonazarov B, Novoyatleva T, Boehm M, et al. p38 MAPK inhibition improves heart function in pressure-loaded right ventricular hypertrophy. Am J Respir Cell Mol Biol. 2017;57(5):603–614. eng.
   PubMed Web of Science ®Google Scholar
• Li SN, Zhang JR, Zhou L, et al. 2021. Sacubitril/valsartan decreases atrial fibrillation susceptibility by inhibiting angiotensin II-induced atrial fibrosis through p-Smad2/3, p-JNK, and p-p38 Signaling Pathways.
   Google Scholar
• Dong B, Chen DF, Bu XH, et al. Effect of imatinib on DOCA-induced myocardial fibrosis in rats through P38 MAPK signaling pathway. Eur Rev Med Pharmacol Sci. 2020;24(4):2028–2036. eng.
   PubMed Web of Science ®Google Scholar
• Kimoto K, Nakatsuka K, Matsuo N, et al. p38 MAPK mediates the expression of type I collagen induced by TGF-beta 2 in human retinal pigment epithelial cells ARPE-19. Invest Ophthalmol Vis Sci. 2004;45(7):2431–2437. eng.
   PubMed Web of Science ®Google Scholar
• Zhao T, Kee HJ, Bai L, et al. Selective HDAC8 inhibition attenuates isoproterenol-induced cardiac hypertrophy and fibrosis via p38 MAPK pathway. Front Pharmacol. 2021;12:677757. eng.
   PubMed Web of Science ®Google Scholar